Bill.com Holdings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Bill.com Holdings Inc trades at $49.11 (market cap $4.93B), while Regeneron Pharmaceuticals Inc trades at $796.8 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 16.6× Bill.com Holdings Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| BILL | REGN | |
|---|---|---|
Market Cap | $4.93B | $82.06B |
Sector | Technology | Health |
52-Week High | $56.32 | $812.27 |
52-Week Low | $31.96 | $555.51 |
Enterprise Value | $4.64B | $76.77B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $49.26, up 2.65% today, showing strong momentum with three consecutive earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth has accelerated from $642M in 2022 to $1.46B in 2025, with the company achieving positive net income for the first time. Recent leadership changes and operational efficiency initiatives, including a 30% workforce reduction, position the company for improved profitability.
The outlook remains positive with 56% analyst buy ratings and a consensus price target of $45.67, though current price exceeds this target. Key risks include high valuation multiples (P/E 213.91) and intense fintech competition. Upside catalysts include continued SMB adoption and AI-driven automation growth, while execution risks and market volatility present challenges for investors seeking exposure to the financial operations software sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →